Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

Background:The renin–angiotensin system (RAS) is thought to have a role in carcinogenesis, and RAS inhibition may prevent tumour growth.Methods:We retrospectively investigated the impact of angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) in 155 patients with pancreatic cancer receiving gemcitabine monotherapy. Patients were divided into three groups: the ACEI/ARB group (27 patients receiving an ACEI or ARB for hypertension (HT)), the non-ACEI/ARB with HT group (25 patients receiving antihypertensive drugs other than ACEIs or ARBs), and the non-HT group (103 patients receiving no antihypertensive drugs).Results:Patient characteristics were not different, except for age and HT medications. Progression-free survival (PFS) was 8.7 months in the ACEI/ARB group, 4.5 months in the non-ACEI/ARB with HT group, and 3.6 months in the non-HT group. Overall survival (OS) was 15.1 months in the ACEI/ARB group, 8.9 months in the non-ACEI/ARB with HT group, and 9.5 months in the non-HT group. The use of ACEIs/ARBs was a significant prognostic factor for both PFS (P=0.032) and OS (P=0.014) in the multivariate analysis.Conclusions:The ACEIs/ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are needed to test this hypothesis.

• Publication year

  2010

• Venue

  British Journal of Cancer

• Publication date

  2010-10-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6605955PMID 20978506PMCID 2994224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells

  2010influential reference
• Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment

  2010cited by this paper
• Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

  2010cited by this paper
• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

  2010cited by this paper
• A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.

  2010cited by this paper
• Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

  2010cited by this paper
• Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.

  2010cited by this paper
• Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

  2009cited by this paper
• The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer

  2009cited by this paper
• Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

  2009cited by this paper
• Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.

  2009influential reference
• Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.

  2009cited by this paper
• Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

  2009cited by this paper
• A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer

  2009cited by this paper
• The renin-angiotensin system and malignancy.

  2008cited by this paper
• Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

  2008cited by this paper
• New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.

  2008cited by this paper
• Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?

  2008influential reference
• Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

  2007cited by this paper
• The physiology of a local renin–angiotensin system in the pancreas

  2007cited by this paper
• Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage.

  2006cited by this paper
• Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

  2005cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

  2005cited by this paper
• Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells.

  2004cited by this paper
• Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues.

  2003cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• New guidelines to evaluate the response to treatment in solid tumors

  2000influential reference
• The tissue renin-angiotensin system in human pancreas.

  1999cited by this paper
• Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

  1998influential reference
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Evidence for an intrinsic angiotensin system in the canine pancreas.

  1991cited by this paper

• Progression from Prehypertension to Hypertension and Risk of Gastrointestinal Cancer-A Nationwide Health-Screening Cohort Study.

  2026cites this paper
• Cancer and Cardiovascular Disease

  2025cites this paper
• The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis

  2025cites this paper
• Effect of antihypertensive drugs on survival in patients with non-small cell lung cancer on epidermal growth factor receptor inhibitors.

  2025cites this paper
• Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer

  2025cites this paper
• Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice

  2025cites this paper
• The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection

  2024cites this paper
• IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone

  2024cites this paper
• Renin–Angiotensin Inhibitor, Captopril, Attenuates Growth of Patient-Derived Colorectal Liver Metastasis Organoids

  2024cites this paper
• The Association between Use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis.

  2024cites this paper
• Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer

  2024cites this paper
• The concomitant use of the renin–angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center

  2024cites this paper
• Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.

  2024cites this paper
• Anti-tumor effects of telmisartan in glioma-astrocyte non-contact co-cultures: A critical role of astrocytic IL-6-mediated paracrine growth promotion.

  2024cites this paper
• Systematic Reversal of Drug Resistance in Cancer

  2024cites this paper
• Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis

  2024cites this paper
• Synergistic effects of calcium channel blockers and renin-angiotensin inhibitors with gemcitabine-based chemotherapy on the survival of patients with pancreatic cancer

  2024cites this paper
• Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel

  2024cites this paper
• Combination of Losartan and Platinum Nanoparticles with Photothermal Therapy Induces Immunogenic Cell Death Effective Against Neuroblastoma

  2024cites this paper
• Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids

  2024cites this paper
• The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies

  2023cites this paper
• Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)

  2023cites this paper
• Prospective of Pancreatic Cancer Diagnosis Using Cardiac Sensing

  2023cites this paper
• The emerging promise of tumour mechanobiology in cancer treatment.

  2023cites this paper
• Antiproliferative and apoptotic effects of telmisartan in human glioma cells

  2023cites this paper
• Antitumor Therapy Targeting the Tumor Microenvironment

  2023cites this paper
• Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis

  2023cites this paper
• Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy

  2023influential citation
• Epigenetic Small-Molecule Screen for Inhibition and Reversal of Acinar Ductal Metaplasia in Mouse Pancreatic Organoids

  2023cites this paper
• Antihypertensive drugs and cancer risk.

  2022cites this paper
• Captopril, a Renin–Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy

  2022cites this paper
• Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer

  2022influential citation
• Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.

  2022cites this paper
• Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis

  2022cites this paper
• Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil

  2022cites this paper
• The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up.

  2022cites this paper
• Increased risk of metastasis in patients with incidental use of renin-angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on electronic medical records

  2022cites this paper
• The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.

  2022cites this paper
• Elemental changes in heart and coronaries after breast cancer radiotherapy assessed by synchrotron radiation soft X-ray spectromicroscopy

  2022cites this paper
• Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment

  2022cites this paper
• The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis

  2022cites this paper
• Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs): a population-based cohort study

  2022cites this paper
• Angiotensin blockade therapy and survival in pancreatic cancer: a population study

  2022cites this paper
• Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy

  2022cites this paper
• The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

  2021cites this paper
• The role of the renin-angiotensin system inhibitors in malignancy: a review.

  2021cites this paper
• Angiotensin II Receptor Blockers Improve Survival in Patients With Locally Advanced Oral Squamous Cell Carcinoma- A Propensity-Score-Matched Study

  2021cites this paper
• The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.

  2021cites this paper
• Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy

  2021cites this paper
• Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study

  2021cites this paper
• Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?

  2021cites this paper
• Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis.

  2020cites this paper
• Review

  2020cites this paper
• Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer.

  2020cites this paper
• The renin–angiotensin system blockers and survival in digestive system malignancies

  2020cites this paper
• GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets

  2020cites this paper
• The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy

  2020cites this paper
• Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins

  2020cites this paper
• Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma

  2020cites this paper
• Angiotensin Inhibition, TGF-β and EMT in Cancer

  2020cites this paper
• Impact of angiotensin system inhibitors on esophageal cancer survival

  2020cites this paper
• Tumor Microenvironment

  2020cites this paper
• A systematic review and meta-analysis

  2020influential citation
• Special Section on Drug Delivery Technologies — Minireview Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.

  2019cites this paper
• Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry.

  2019cites this paper
• 345 – Non-Selective β-Adrenergic Blockade Impacts Pancreatic Cancer Tumor Biology, Decreases Perineural Invasion and Improves Patient Survival

  2019cites this paper
• Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers

  2019cites this paper
• The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment

  2019cites this paper
• Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• Ciblage pharmacologique du microenvironnement de l'adénocarcinome canalaire pancréatique

  2018cites this paper
• Potential anti-tumor mechanisms of renin angiotensin system inhibitors through inhibiting angiogenesis and influencing angiotensin II actions

  2018cites this paper
• Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer

  2018cites this paper
• The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior

  2018cites this paper
• Pancreatic Cancer Epidemiology and Environmental Risk Factors

  2018cites this paper
• The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship

  2018cites this paper
• The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis.

  2018cites this paper
• The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome.

  2017cites this paper
• Nanoparticle‐based hyperthermia, a local treatment modulating the tumor extracellular matrix

  2017cites this paper
• The prognostic significance of hypertension at diagnosis in children with wilms tumor

  2017cites this paper
• All‐trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC‐1 by up‐regulating protein expression of deoxycytidine kinase

  2017influential citation
• Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small‐Cell Lung Cancer

  2017cites this paper
• Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma

  2017influential citation
• Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?

  2017cites this paper
• Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database
.

  2017cites this paper
• Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.

  2017cites this paper
• The Solid Mechanics of Cancer and Strategies for Improved Therapy.

  2017cites this paper
• Antiangiogenic Therapy for Hepatocellular Carcinoma

  2017cites this paper
• The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma

  2017cites this paper
• implemented. For patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), a number of clinical trials have been conducted; NACRT was demonstrated to improve resectability, R0 resection rate, overall survival rate, disease-free survival rate and even

  2017cites this paper
• Pancreatic stellate cells in pancreatic cancer: In focus.

  2017cites this paper
• Use of inhibitors of the renin angiotensin system is associated with longer survival in patients with hepatocellular carcinoma

  2017cites this paper
• Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer

  2017influential citation
• Angiotensin II type 2 receptor signalling promotes glioblastoma growth : a novel target for therapeutic intervention

  2017cites this paper
• Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

  2017cites this paper
• Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

  2017cites this paper
• The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis

  2017influential citation
• Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.

  2016cites this paper
• No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer.

  2016cites this paper